In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: Correlation with clinico-hematological and immunophenotypic features

Haematologica

Volumn 81, Issue 3, 1996, Pages 224-231

  Morabito, Fortunato ^a   Stelitano, Caterina ^a   Callea, Ida ^a   Filangeri, Monica ^a   Oliva, Bianca ^a   Sculli, Giuseppina ^a   Callea, Vincenzo ^a   Nobile, Francesco ^a   Brugiatelli, Maura ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

2 chlorodeoxyadenosine; Chemosensitivity; Chlorambucil; CLL; Fludarabine

Indexed keywords

CHLORAMBUCIL; CLADRIBINE; FLUDARABINE; FLUDARABINE PHOSPHATE; PURINE DERIVATIVE;

ARTICLE; B LYMPHOCYTE; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LD 50;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CHLORAMBUCIL; CLADRIBINE; HEMATOLOGIC TESTS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC; VIDARABINE;

EID: 0030322149     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. O'Brien S, Del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995; 85:307-18.
2. Faguet G. Chronic lymphocytic leukemia: an updated review. J Clin Oncol 1994; 12:1974-90.
3. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 19:1052-7.
4. Jaksic B, Brugiatelli M. High dose continuous chlorambucil vs. intermittent chlorambucil plus prednisone for treatment of B-CLL - IGCI CLL-01 trial. Nouv Rev Fr Hematol 1988; 30:437-42.
5. Montserrat E, Rozman C. Chronic lymphocytic leukemia treatment. Blood Rev 1993; 7:164-75.
6. Keating MJ, Kantarjian HM, Talpaz M, et al. Fludarabine a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74:19.
7. O'Brien S, Kantarjan H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82:1695-704.
8. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72:1069-73.
9. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993; 11: 679-89.
10. Catovsky D, Cherchi M, Brooks D, Bredley J, Zola H. Heterogeneity of B cell leukemia demonstrated by the monoclonal antibody FMC7. Blood 1981; 58:406-8.
11. Pinto A, Zagonel V, Carbone A, et al. Expression of myelomonocytic antigens on chronic lymphocytic leukemia B cells identifies a subset of patients with a "variant" CLL phenotype and different biological and clinical features. (abstr). Proceedings of American Society of Clinical Oncology 1989; pp. 204.
12. + chronic B-cell leukemias and the identification of novel peripheral blood B-cell subsets with chronic lymphoid leukemia immunophenotypes. Blood 1990; 76:123-30.
13. Morabito F, Prasthofer EF, Dunlap NE, Grossi CE, Tilden AB. Expression of myelomonocytic antigens on chronic lymphocytic leukemia B cells correlates with their ability to produce interleukin 1. Blood 1987; 70:1750-7.
14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Meth 1983; 65:55-63.
15. Hanson JA, Bentley DP, Bean EA, Sarah R, Nute SR, Moore JL. In vitro chemosensitivity testing in chronic lymphocytic leukaemia patients. Leuk Res 1991; 15:565-9.
16. Morabito F, Messina G, Oliva B, et al. In vitro chemosensitivity of chronic lymphocytic leukemia B-cells to multidrug regimen (CEOP) compounds using the MTT colorimetric assay. Haematologica 1993; 78:213-8.
17. Zinzani PL, Tosi P, Visani G, et al. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. Am J Hematol 1994; 47:301-6.
18. Silber R, Degar B, Costin D, et al. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood 1994; 84: 3440-60.
19. Morabito F, Callea I, Rodinò A, et al. Modulation of purine analogs- and chlorambucil-induced cytotoxicity by alpha-interferon and interleukin-2 in chronic lymphocytic leukemia. Leukemia 1995; 9:1425-33.
20. International Workshop on CLL. Chronic lymphocytic leukemia: recommendation for diagnosis, staging, and response evaluation. Ann Intern Med 1989; 110:236-8.
21. Jaksic B, Vitale B. Total Tumor Mass score (TTM): a new parameter in chronic lymphocytic leukaemia. Br J Haematol 1981; 49:401-13.
22. Liliemark J, Pettersson B, Juliusson G. The relationship between plasma 2-chlorodeoxyadenosine (CdA) and cellular CdA nucleotides (CdAN) after intermittent and continuous I.V. in patients with chronic lymphocytic leukemia. (abstr.) Blood 1991; 78 (suppl 1):33a.
23. Danhauser L, Plunkett W, Keating M, Cabanillas F. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 1986; 18:142-5.
24. Adair CG, Bridges JM, Desai ZR. Can food affect the biovailability of chlorambucil in patients with haematological malignancies? Cancer Chemother Pharmacol 1986; 17:99-102.
25. Saven A, Lemon RH, Kosky M, Beutler E, Piro LD. 2-chlorodeoxyadenosine (2-CDA) activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13:570-4.
26. Brugiatelli M, Jaksic B, Planinc-Peraica A, et al. Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: long-term results of a randomized trial. Eur J Haematol 1995; 55:158-63.
27. Begleiter A, Verburg L, Ashique A, et al. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-β-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995; 9:1875-81.
28. Juliusson G, Elmhorn-Rosemberg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327:1056-61.
29. O'Brian S, Kantaryian H, Estey E, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994; 330:319-22.